Terazosin and Parkinson's Disease Extension Study

Description

The purpose of this study is to investigate the long-term effects of treatment with the selective post-synaptic a1-adrenergic blocker terazosin on serial in a population of subjects with defined pre-motor Parkinson's disease (PD) risks and abnormal imaging exams. Imaging changes will be correlated to the presence and severity of motor and non-motor symptoms of PD, measured by validated clinical scales and cardiac autonomic function tests.

Conditions

Symptomatic Parkinson Disease, REM Sleep Behavior Disorder, Pre-motor Parkinson's Disease

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to investigate the long-term effects of treatment with the selective post-synaptic a1-adrenergic blocker terazosin on serial in a population of subjects with defined pre-motor Parkinson's disease (PD) risks and abnormal imaging exams. Imaging changes will be correlated to the presence and severity of motor and non-motor symptoms of PD, measured by validated clinical scales and cardiac autonomic function tests.

The Effect of Alpha1- Adrenergic Receptor Antagonist Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease: a Follow Up Study

Terazosin and Parkinson's Disease Extension Study

Condition
Symptomatic Parkinson Disease
Intervention / Treatment

-

Contacts and Locations

Los Angeles

Cedars Sinai Medical Center, Los Angeles, California, United States, 90048

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Enrolled in the study "The Effect of alpha1- adrenergic receptor antagonist Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease" (STUDY #000540)
  • * Capacity to give informed consent
  • * Secondary Parkinsonism, including tardive
  • * Concurrent dementia defined by a score lower than 22 on The Montreal Cognitive Assessment (MoCA)
  • * Concurrent severe depression defined by a Beck Depression Inventory-Fast Screen (BDI fast screen) score greater than 13
  • * Comorbidities related to sympathetic nervous system (SNS) hyperactivity
  • * Heart failure (LVEF \<45%)
  • * Recent myocardial revascularization (\<12 weeks)
  • * Hypertension (systolic blood pressure SBP\>150mmHg (millimeters of mercury) or diastolic blood pressure DBP\>100mmHg)
  • * Chronic Atrial fibrillation
  • * Concurrent Use of Beta-adrenergic antagonist
  • * Diabetes mellitus
  • * Chronic Obstructive Pulmonary Disease (COPD)
  • * Untreated Sever Sleep Apnea; Apnea-Hypopnea Index (AHI) \> 30/h.
  • * Severely reduced kidney function (Glomerular Filtration Rate\<30ml/min)
  • * Contraindications to the use of terazosin
  • * Recent myocardial infarction (\<48 h)
  • * Ongoing angina pectoris
  • * Cardiogenic shock or prolonged hypotension
  • * Breast-feeding
  • * Current use of phosphodiesterase type 5 inhibitors: sildenafil (ViagraTM), tadalafil (CialisTM), or vardenafil (LevitraTM)
  • * History of priapism (persistent and painful erection)
  • * Neurogenic orthostatic hypotension defined as symptomatic decrease in BP \> 20mmHg systolic or \> 10mmHg diastolic and HR increase \< 20bpm on supine to sitting or standing.
  • * Blood pressure less than 110 mm Hg systolic at screening or baseline visit
  • * Use of investigational drugs within 30 days before screening
  • * For female participant, pregnancy, or plans for child-bearing during study period
  • * Allergy/hypersensitivity to iodine or study medication

Ages Eligible for Study

50 Years to 85 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Cedars-Sinai Medical Center,

Michele Tagliati, MD, FAAN, PRINCIPAL_INVESTIGATOR, Cedars-Sinai Medical Center

Study Record Dates

2025-11-01